




INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



R. Mahoney

Signed

Dated 24 September 2003

Patent Act 1977
(Rule 16)



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Concept House
Cardiff Road
Newport
South Wales NP10 8QQ

1. Your reference SCB/NLW/60516/000 24SEP02 E750430-1 002882
P01/7700 0.00-0222078.8

2. Patent application number (The Patent Office will fill in this part) 0222078.8 23 SEP 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames) GW PHARMA LIMITED
PORTON DOWN SCIENCE PARK
SALISBURY
WILTSHIRE
SP4 0JQ

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

UNITED KINGDOM

4. Title of the invention METHOD OF PREPARING CANNABIDIOL FROM PLANT MATERIAL

5. Name of your agent (if you have one) BOULT WADE TENNANT
VERULAM GARDENS
70 GRAY'S INN ROAD
LONDON WC1X 8BT

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Patents ADP number (if you know it)

42001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? YES

(Answer 'Yes' if:
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Patents Form 1/77

9. Enter the number of sheets for each of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 24

Claim(s) 4

Abstract 0 *DM*

Drawing(s) 4+4

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) 1 ✓

Request for substantive examination (Patents Form 10/77)

Any other documents
(Please specify)

11

I/We request the grant of a patent on the basis of this application.

Signature

Date

Boul Wade Tennant

23 September 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Nina L White
020 7430 7500

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

Method of preparing cannabidiol from plant material

Field of the invention

5 The invention relates to methods of preparing cannabidiol in substantially pure form starting from plant material.

Background to the invention

10 Cannabis has been used medicinally for many years, and in Victorian times was a widely used component of prescription medicines. It was used as a hypnotic sedative for the treatment of "hysteria, delirium, epilepsy, nervous insomnia, migraine, pain and dysmenorrhoea". Historically, cannabis was
15 regarded by many physicians as unique; having the ability to counteract pain resistant to opioid analgesics, in conditions such as spinal cord injury, and other forms of neuropathic pain including pain and spasm in multiple sclerosis.

20 The use of cannabis continued until the middle of the twentieth century, when the recreational use of cannabis prompted legislation which resulted in the prohibition of its use. The utility of cannabis as a
25 prescription medicine is now being re-evaluated. The discovery of specific cannabinoid receptors and new methods of administration have made it possible to extend the use of cannabis-based medicines to historic and novel indications.

30 The principle cannabinoid components present in herbal cannabis are the cannabinoid acids Δ^9 tetrahydrocannabinolic acid (Δ^9 THCA) and cannabidiolic acid (CBDA), with small amounts of the
35 corresponding neutral cannabinoids, respectively Δ^9 tetrahydrocannabinol (Δ^9 THC) and cannabidiol (CBD).

Cannabidiol (CBD) was formerly regarded as an inactive constituent, however there is emerging evidence that it has pharmacological activity, which is different from that of Δ^9 THC in several respects.

5

Wider studies of the pharmacology of CBD are needed in order to fully explore its pharmaceutical potential. Thus, there is a need for substantially pure preparations of CBD for use in such studies.

10

Synthetic forms of cannabidiol are commercially available (e.g. from Sigma Corp.) but are prohibitively expensive. Furthermore, HPLC analysis reveals the presence of a significant amounts of Δ^9 THC (typically around 1%) in the commercially available preparations of cannabidiol.

15

Thus, there is a need for a method of production of cannabidiol which is inexpensive and yet capable of yielding substantially pure cannabidiol, particularly cannabidiol containing less Δ^9 THC than the currently available preparations.

20

The inventors have therefore focussed on the purification of CBD from plant material and have developed a process for the preparation of substantially pure crystalline CBD from plant material.

25

30 Summary of the invention

In a first aspect the invention provides a method of obtaining substantially pure cannabidiol (CBD) from plant material, which method comprises obtaining a cannabidiol-containing extract of the plant material, dissolving the extract in a solvent to form a solution, removing insoluble material from this solution and evaporating the solvent from the solution

35

to obtain substantially pure cannabidiol.

In a second aspect the invention provides a substantially pure preparation of cannabidiol (CBD) having a chromatographic purity of 95% or greater, preferably 96% or greater, more preferably 97% or greater, more preferably 98% or greater, more preferably 99% or greater and most preferably 99.5% or greater by area normalisation of an HPLC profile.

Description of the invention

The invention relates to a purification process for preparing substantially pure cannabidiol (CBD) from plant material.

A "substantially pure" preparation of cannabidiol (CBD) is defined as a preparation having a chromatographic purity of 95% or greater, more preferably 96% or greater, more preferably 97% or greater, more preferably 98% or greater, more preferably 99% or greater, and most preferably 99.5% or greater as determined by area normalisation of an HPLC profile.

The process of the invention involves obtaining a cannabidiol-containing extract from a plant material, dissolving the extract in a solvent to form a solution, removing insoluble material from this solution (preferably by filtration) and evaporating the solvent from the solution (for example by rotary evaporation) to obtain substantially pure cannabidiol.

In a preferred embodiment substantially pure cannabidiol is obtained in crystalline form.

The solvent used to re-dissolve the cannabidiol-containing extract is preferably a non-polar liquid

solvent. The purpose of this solvent treatment step is to remove non-cannabidiol impurities to leave a substantially pure preparation of cannabidiol. Suitable non-polar solvents therefore include
5 essentially any non-polar solvents which are substantially less polar than cannabidiol, such that impurities which are more polar than cannabidiol are removed by treatment with the solvent. Preferred non-polar solvents include C5-C12 straight chain or
10 branched chain alkanes, or carbonate esters of C1-C12 alcohols. It is preferred to use the more volatile C5-C12 alkanes, as they are more easily removed by evaporation. Particularly preferred solvents include pentane (preferably n-pentane), hexane (preferably n-
15 hexane) and propyl carbonate.

The method of the invention may be used to prepare substantially pure cannabidiol from any plant material known to contain cannabidiol (CBD), or the
20 corresponding cannabinoid acid cannabidiolic acid (CBDA). Most typically, but not necessarily, the "plant material" will be derived from one or more cannabis plants.

25 The term "plant material" encompasses a plant or plant part (e.g. bark, wood, leaves, stems, roots, flowers, fruits, seeds, berries or parts thereof) as well as exudates, and includes material falling within the definition of "botanical raw material" in the
30 Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research.

35 The term "cannabis plant(s)" encompasses wild type *Cannabis sativa* and also variants thereof, including cannabis chemovars (varieties characterised

by virtue of chemical composition) which naturally contain different amounts of the individual cannabinoids, also *Cannabis sativa* subspecies *indica* including the variants *var. indica* and
5 *var. kafiristanica*, *Cannabis indica* and also plants which are the result of genetic crosses, self-crosses or hybrids thereof. The term "cannabis plant material" is to be interpreted accordingly as encompassing plant material derived from one or more
10 cannabis plants. For the avoidance of doubt it is hereby stated that "cannabis plant material" includes herbal cannabis and dried cannabis biomass.

It is preferred to use cannabis plant material
15 derived from cannabis plants having a relatively high content of CBD (as CBDA and/or CBD). With the use of standard selective breeding techniques the present inventors have developed cannabis varieties (chemovars) having a CBDA/CBD content of >90% of the
20 total cannabinoid content.

If the plant material from which CBD is to be prepared contains significant amounts of the cannabinoid acid CBDA then the plant material may be
25 subjected to a decarboxylation step to convert CBDA to the free cannabinoid CBD. This is preferably carried out prior to preparation of the CBD-containing plant extract or may form part of this extraction process.

Decarboxylation is preferably carried out by
30 heating the plant material to a defined temperature for a suitable length of time. Decarboxylation of cannabinoid acids is a function of time and temperature, thus at higher temperatures a shorter
35 period of time will be taken for complete decarboxylation of a given amount of cannabinoid acid.

Preferably, decarboxylation is carried out in a multi-step heating process in which the plant material is:

- 5 i) heated to a first temperature for a first (relatively short) time period to evaporate off retained water and allow for uniform heating of the plant material; and
- 10 ii) the temperature is increased to a second temperature for a second time period (typically longer than the first time period) until at least 95% conversion of the acid cannabinoids to their neutral form has occurred.

15 Preferably the first step is conducted at a temperature in the range of 100°C to 110°C for 10-20min. More preferably the first temperature is about 105°C and the first time period is about 15 minutes.

20 Optimum times and temperatures for the second step may vary depending on the nature of the plant material, and more particularly on the cannabinoid which it is intended to isolate from the plant material, and may be easily determined by routine
25 experiment. Suitable conditions may include, for example, a temperature in the range from 115°C to 125°C for a time period in the range from 45 to 75 minutes (typically 120°C for 60 minutes), or a
30 temperature in the range from 135°C to 145°C, for a time period in the range from 15 to 45 minutes.

If the plant material is derived from cannabis plants having a high CBD content (defined as >90% CBD as a percentage of total cannabinoid content), the
35 second temperature is preferably in the range from 115°C to 125°C, preferably about 120°C and the second time period is in the range from 45 to 75 minutes,

preferably about 60 minutes. More preferably the second temperature is in the range from 135°C to 145 °C, preferably 140°C and the second time period is in the range from 15 to 45 minutes, preferably about 30 minutes. In another embodiment, most preferred for a mass of plant material greater than 4kg, the second temperature is in the range from 140°C to 150°C, preferably 145°C and the second time period is in the range from 55-90 minutes. The exact figures, particularly time, may vary slightly with increased mass. This should be taken into account when scaling up the process to an industrial manufacturing scale.

Where the starting "plant material" is freshly harvested or "wet" plant material is may be subjected to a drying step to remove excess moisture prior to step (i). For convenience, decarboxylation and drying may be combined in a single heating step or in a multi-step heating process, as described above.

The "cannabidiol-containing extract" is preferably a botanical drug substance prepared from plant material, or an ethanolic solution of such a botanical drug substance. In the context of this application a "botanical drug substance" is defined as an extract derived from plant material, which extract fulfils the definition of "botanical drug substance" provided in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research of: "A drug substance derived from one or more plants, algae, or macroscopic fungi. It is prepared from botanical raw materials by one or more of the following processes: pulverisation, decoction, expression, aqueous extraction, ethanolic extraction, or other similar processes."

"Botanical drug substances" derived from cannabis plants include primary extracts prepared by such processes as, for example, maceration, percolation, and solvent extraction. Solvent extraction may be carried out using essentially any solvent that dissolves cannabinoids/cannabinoid acids, such as for example C1 to C5 alcohols (e.g. ethanol, methanol), C5-C12 alkanes (e.g. hexane), Norflurane (HFA134a), HFA227 and carbon dioxide. When solvents such as those listed above are used, the resultant extract typically contains non-specific lipid-soluble material. This can be removed by a variety of processes including "winterisation", which involves chilling to -20°C followed by filtration to remove waxy ballast, extraction with liquid carbon dioxide and by distillation. General protocols for the preparation of botanical drug substances from cannabis plant material are described in the applicant's published International patent application WO 02/064109.

The botanical drug substance is preferably obtained by carbon dioxide (CO₂) extraction followed by a secondary extraction, e.g. an ethanolic precipitation, to remove a substantial proportion of non-cannabinoid materials, e.g. waxes, wax esters and glycerides, unsaturated fatty acid residues, terpenes, carotenes, and flavenoids and other ballast. Most preferably the botanical drug substance is produced by a process comprising extraction with liquid CO₂, under sub-critical or super-critical conditions, and then a further extraction, preferably an ethanolic precipitation, to remove significant amounts of ballast.

The resulting ethanolic BDS solution may be subjected to further treatment with activated

charcoal. Conveniently, this may be achieved by passing the ethanolic BDS solution down a column of activated charcoal.

- 5 Thus, in the most preferred embodiment the botanical drug substance is prepared according to a process comprising the following steps:
- i) decarboxylation of the plant material,
 - 10 ii) extraction with liquid CO₂ (most preferably under sub-critical conditions), to produce a crude botanical drug substance,
 - iii) precipitation with C1-C5 alcohol (preferably ethanol) to reduce the proportion of non-target materials,
 - 15 iv) removal of the precipitate (preferably by filtration),
 - v) optional treatment with activated charcoal, and
 - vi) evaporation to remove C1-C5 alcohol and water, thereby producing a final botanical drug substance.

20

A detailed example of such a process is described in the accompanying Examples.

- The most preferred embodiment of the purification method therefore comprises:
- 25

- i) decarboxylation of the plant material,
- ii) extraction with liquid CO₂ (most preferably under sub-critical conditions), to produce a crude botanical
- 30 drug substance,
- iii) precipitation with C1-C5 alcohol (preferably ethanol) to reduce the proportion of non-target materials,
- iv) filtration to remove the precipitate,
- 35 v) treatment of the resulting solution with activated charcoal,
- vi) removal of the C1-C5 alcohol and any water from

the solution to produce a CBD-enriched extract,
v) re-dissolving the CBD-enriched extract in pentane,
vi) removal of any insoluble material, if required,
vi) removal of solvent from resulting solution,
5 preferably by evaporation, thereby crystallising
cannabidiol.

The process of the invention yields substantially
pure cannabidiol of high chromatographic purity,
10 typically as a white crystalline solid.

The invention further relates to a substantially
pure preparation of cannabidiol having a
chromatographic purity of 95% or greater, more
15 preferably 96% or greater, more preferably 97% or
greater, more preferably 98% or greater, preferably
99% or greater, and most preferably 99.5% or greater
by area normalisation of an HPLC profile. The
preparation is typically a white crystalline solid at
20 room temperature, having a melting point in the range
of from 64 to 66°C.

The preparation preferably comprises less than
1%, more preferably less than 0.8%, more preferably
25 less than 0.6%, more preferably less than 0.4%, more
preferably less than 0.2% and most preferably less
than 0.1% Δ^9 THC.

The preparation preferably comprises less than
30 1%, more preferably less than 0.8%, more preferably
less than 0.6%, more preferably less than 0.4%, more
preferably less than 0.2% and most preferably less
than 0.1% CBN.

35 Most preferably the preparation contains no
detectable CBN or Δ^9 THC, defined as less than 0.1% by
HPLC analysis.

The inventors are the first to isolate CBD from plant material at this level of purity in crystalline form. The ability to prepare CBD at a high level of purity will permit further studies of the pharmacology, and hence pharmaceutical utility, of this cannabinoid.

The substantially pure cannabidiol provided by the invention is significantly more pure than the cannabidiol (CBD standard) commercially available from Sigma Corporation (see comparative HPLC analysis, Figure 3). Of particular significance is the fact that cannabidiol prepared according to the invention contains no detectable Δ^9 THC (less than 0.1% by HPLC), whereas the Sigma CBD standard contains ~1% Δ^9 THC.

The invention will be further understood with reference to the following experimental examples, together with the accompanying Figures, in which:

Figure 1 shows thin layer chromatography (TLC) profiles of purified cannabidiol (CBD), as compared to the starting material (CBD-containing botanical drug substance) and CBD and THC standards (Sigma). Standards were 1 mg/ml CBD (BN 10601/c) or Δ^9 THC (BN 10601/B) in MeOH, 5 μ l of each applied to TLC plate. Samples were 1 mg/ml CBD starting material in MeOH, 5 μ l applied to TLC plate, 1 mg/ml crystalline CBD in MeOH, 5 μ l applied to TLC plate.

Figure 2 shows sample HPLC profiles of CBD starting material (botanical drug substance) and purified, crystalline CBD. HPLC was performed as described in the examples.

Figure 3 shows sample HPLC profiles of purified

crystalline CBD (99.6% purity by area normalisation) and Sigma CBD standard (93% CBD, 1% THC).

5 Figure 4 shows gas chromatographic (GC) analysis of CBD starting material (botanical drug substance) and purified, crystalline CBD.

Example 1-Purification of CBD

10 Overview of process

Starting from freshly harvested plant material the process comprises drying and decarboxylation of the plant material, optional treatment (e.g. milling) of the dried plant material to reduce the particle
15 size (preferably to less than 2000µm), extraction with liquid carbon dioxide, ethanolic precipitation to reduce the amount of non-target material, clean-up of the crude ethanolic extract by passage through activated charcoal, removal of solvent (ethanol) to
20 produce a CBD-enriched fraction, and re-crystallisation of CBD from pentane.

Plant material

25 GW Pharma Ltd has developed distinct varieties of Cannabis plant hybrids to maximise the output of the specific chemical constituents, cannabinoids. A "high CBD" chemovar designated G5 produces >90% total cannabinoid content as CBD (naturally occurring in the plant in the form of CBDA). Alternative "high CBD"
30 varieties can be obtained - see for example, Common cannabinoids phenotypes in 350 stocks of cannabis, Small and Beckstead, Lloydia vol 36b , 1973 p144-156 - and bred using techniques well known to the skilled man to maximise cannabinoid content.

35

General protocols for growing of medicinal cannabis and for testing the cannabinoid content of

cannabis plants are described in the applicant's published International patent application WO 02/064109.

5 Solvents

 All solvents used in the isolation and analysis of CBD (e.g n-pentane) were, unless otherwise stated, of chromatographic or A.R. grade.

10 Standards

 Reference materials from Sigma were used as standards in the analysis of extracts, intermediates and finished products, these were: Δ^9 THC in methanol BN 10601/B (ca. 1 mg/ml) and CBD in methanol BN 10601/C (ca. 1 mg/ml).

Preparation of a cannabidiol-containing extract

 A cannabidiol-containing extract is prepared from a "high CBD" cannabis chemovar according to the following process:

 Prepare ethanolic solution of botanical drug substance as follows:

25 harvest cannabis plant material, dry, reduce particle size by milling to less than 2000 μ m

↓

 decarboxylate milled plant material by heating to approximately 105°C for 15 minutes, followed by approximately 145°C for minimum of 55 minutes (NB decarboxylation time and temperature may be varied)

↓

30 extract with liquid carbon dioxide (CO₂) [Food Grade] for up to 10 hours Conditions: Approximately 60 bar \pm 10 bar pressure and 10°C \pm 5°C

↓

Removal of CO₂ by depressurisation to recover crude
extract

↓

5 "Winterisation"-Dissolution of crude extract in
ethanol followed by chilling solution
(-20°C ± 5°C/up to 52hours) to precipitate unwanted
waxes

↓

10 Removal of unwanted waxy material by cold filtration
(20mm filter)

↓

ethanolic solution of BDS
(Stored at -20°C ± 5°C)

15 Extraction using liquid CO₂ is carried out under
sub-critical conditions at a temperature of
approximately 10°C ± 5°C using a pressure of
approximately 60 bar ± 10 bar. Decarboxylated plant
material is packed into a single column and exposed to
20 liquid CO₂ under pressure for approximately 8 hours,
CO₂ mass flow 1250 kg/hr ± 20%.

Following depressurisation and venting off of the
CO₂ the crude BDS extract is collected into sealed
25 vessels. The crude BDS extract is held at -20°C ±
5°C.

The crude BDS extract contains waxes and long
chain molecules. Removal is by "winterisation",
30 whereby the crude BDS extract is warmed to e.g. 40°C ±
4°C to liquefy the material. Ethanol is added in the
ratio of 2:1 ethanol volume to weight of crude BDS
extract. The ethanolic solution is then cooled to
-20°C ± 5°C and held at this temperature for
35 approximately 48 hours.

On completion of the winterisation the precipitate is removed by cold filtration through a 20µm filter, to give an ethanolic solution of the BDS.

5 Preliminary charcoal clean-up may be carried out by passing the ethanolic BDS solution (400-500 mg/ml) through a disposable plastic column (130 mm x 27 mm i.d) packed with activated charcoal (decolourcarb DCL GDC grade, from Sutcliffe Speakman Carbons, 15.4 g per unit). Absolute ethanol B.P. (Hayman) is used as the solvent.

15 Ethanol and any water that may be present are removed by rotary evaporation or thin film evaporation under reduced pressure ($60^{\circ}\text{C} \pm 2^{\circ}\text{C}$, with vapour at $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / 172 mbar and 72 mbar ± 4 mbar) to produce a CBD-rich extract.

Solvent re-crystallisation

20 The CBD-rich extract is re-dissolving in a suitable solvent (e.g. n-pentane) and filtered to remove insoluble material. Solvent is then removed, e.g. by rotary evaporation, to produce crystalline CBD. All steps are carried out according to standard laboratory procedures, such as would be known to those skilled in the art.

Product characteristics

Yield:

30 3 g of CBD BDS yields approx 1 g of purified CBD.

Characteristics:

White crystalline solid.

35 Chromatographic purity > 99% CBD by area normalization.

Chromatographic purity superior to commercially available CBD Sigma standard (refer to Figures 1 and 3).

5 THC non detected i.e. < 0.1%
 CBN non detected i.e. < 0.1%

Identity confirmed by HPLC, GC and TLC retention behaviour compared to CBD Sigma standard.

10

Assay vs both Sigma CBD std in range 98.0-102.0%

Melting Point = 64-66°C (literature value = 66-67°C).

15

HPLC analysis

The composition of the isolated products may be determined by HPLC analysis.

20

A typical HPLC assay for Δ^9 THC, Δ^9 THCA, CBD, CBDA and CBN may be carried out as follows:

a) Materials and methods

25

Chromatography Equipment and conditions:

Equipment Agilent (HP)1100 HPLC system with
 variable wavelength UV detector or
 diode array detector.

HPLC Column Discovery C8 5 μ m 15cm x 0.46cm

30

Pre-Column Kingsorb C18 5 μ m 3cm x 0.46cm

Mobile Phase Acetonitrile : Methanol : 0.25% w/v
 acetic acid (16:7:6 by volume)

Column Temp 25°C

Flow Rate 1.0ml min⁻¹

35

Detection 220nm 600mA f.s.d. Second wavelength
 310nm

Injection Volume 10 μ l

Run Time 20-25 minutes (may be extended for
samples containing small amount of
late-eluting peaks)
Elution Order CBD, CBDA, Δ^9 THCV, CBN, Δ^9 THC, CBC, Δ^9
5 THCA

b) Sample preparation

- 10 Samples of "pure" cannabidiol are diluted in methanol
prior to HPLC analysis. Optimal dilutions may be
determined empirically.
- 15 Herbal cannabis samples are prepared by taking a 100mg
sample and treating this with 5 or 10ml of
Methanol/Chloroform (9/1 w/v). The dispersion is
sonicated in a sealed tube for 10 minutes, allowed to
cool and an aliquot is centrifuged and suitably
20 diluted with methanol prior to chromatography.

c) Standards

- 25 Stock standard solutions of CBD, CBN and Δ^9 THC in
methanol at approximately 1mg ml⁻¹ are stored at
-20°C. Diluted working standards (0.1 mg/ml for Δ^9
THC and CBD and 0.01 mg/ml for CBN) are prepared in
methanol from the stock standards and stored at -20°C
(maximum period of twelve months after initial
30 preparation). After preparation, standard solutions
must be aliquoted into vials to reduce the amount of
standard exposed to room temperature. Prior to use in
an HPLC sample assay, the required number of standard
vials are removed and allowed to equilibrate to room
35 temperature.

Injection of each standard is made in triplicate prior
to the injection of any test solution. At suitable

intervals during the processing of test solutions,
repeat injections of standards are made. In the
absence of reliable CBDA and Δ^9 THCA standards, these
compounds are analysed using respectively the CBD and
5 Δ^9 THC standard response factors.

d) Test solutions

Diluted test solutions are made up in methanol and
10 should contain analytes in the linear working range of
0.02-0.2 mg/ml.

e) Chromatography Acceptance Criteria:

15 The following acceptance criteria are applied to the
results of each sequence as they have been found to
result in adequate resolution of all analytes
(including the two most closely eluting analytes CBD
and CBDA)

20

Table 1- Retention time windows and Relative Retention
Time (RRT) to Δ^9 THC for each analyte

Cannabinoid	Retention time (minutes)	RRT (THC)
25 CBD	5.1-5.8	0.58
CBN	7.4-8.3	0.83
Δ^9 THC	9.0-10.0	1.00
CBDA	5.5-6.2	0.615
Δ^9 THCV	5.9-6.2	0.645
30 CBC	11.6-12.8	1.30
Δ^9 THCA	14.6-16.0	1.605

Table 2- Peak Shape (Symmetry Factor according to
35 British Pharmacopoeia method)

Cannabinoid	Symmetry factor
CBD	<1.30
CBN	<1.25
Δ^9 THC	<1.35

5

f) Data Processing

10 Cannabinoids can be subdivided into neutral and
acidic- the qualitative identification can be
performed using the DAD dual wavelength mode. Acidic
cannabinoids absorb strongly in the region of
220nm-310nm. Neutral cannabinoids only absorb
strongly in the region of 220nm.

15

Routinely, only the data recorded at 220 nm is used
for quantitative analysis.

20

The DAD can also be set up to take UV spectral scans
of each peak, which can then be stored in a spectral
library and used for identification purposes.

25

Data processing for quantitation utilises batch
processing software on the Hewlett Packard
Chemstation.

g) calculation:

30

Chromatographic purity of cannabinoid samples is
calculated as a % of total cannabinoid content by area
normalization.

35

Capillary gas chromatography (GC) analysis

a) Chromatography equipment and conditions

	Equipment	Agilent (HP) 5890 or 6890 GLC system with HP7673 Autosampler and FID detector
5	GLC column	SE54(EC5) 30m x 0.32mm i.d. (Alltech) phase thickness 0.25 μ m
	Flow rate	Constant pressure (10.3 psi). Normal initial flow rate 34cm sec ⁻¹ (2.0 ml min ⁻¹)
10	Column oven	70°C initially then ramp 5°C min ⁻¹ to 250°C. Hold at 250°C for 15 minutes.
	Injector temp	250°C
	Detector temp	325°C
	Injection Vol	1 μ l, split ratio 2.5:1
	Run time	45 minutes
15	Fuel gases	Hydrogen 40 ml min ⁻¹ Air 450 ml min ⁻¹ Helium 45 ml min ⁻¹

20 b) Standard preparation

Stock standard solutions of CBD, CBN and Δ^9 THC in methanol at approximately 1mg ml⁻¹ are stored at -20°C. Diluted working standards (0.1 mg/ml for Δ^9 THC and CBD and 0.01 mg/ml for CBN) are prepared in methanol from the stock standards and stored at -20°C (maximum period of twelve months after initial preparation). Allow an aliquot pipetted into an autosampler vial to equilibrate to room temperature prior to use in a GC assay.

c) Sample preparation

35 Samples of final products, i.e. "pure" cannabidiol, are diluted in methanol prior to HPLC analysis. Optimal dilutions may be determined empirically.

Cannabis plant material samples are prepared by taking 100mg chopped dried material and treating this with 5 or 10ml of Methanol/Chloroform (9:1 v/v). Extract the sample in an ultrasonic bath for 15 minutes and allow to stand in the dark for 18 hours.

d) Chromatography procedure

Standard solutions are used to provide quantitative and retention time data. These can be typically injected in triplicate prior to the injection of any sample solutions and then singularly at suitable intervals during the run, with a maximum of 10 test samples in between standards.

Table 3-Retention times

THCV	33.7-34.5 minutes
CBD	35.6-36.3 minutes
Δ^9 THC	37.2-38.1 minutes
CBN	38.5-39.1 minutes

TLC analysis

The qualitative composition of final products and starting materials may also be monitored by TLC.

TLC uses both retention time and characteristic spot colour to effectively identify the cannabinoid/cannabinoid acid components in a complex mixture. Methanolic solutions of the final products and starting material, plus standards, are prepared for TLC. An aliquot is spotted onto a TLC plate, alongside suitable reference samples (e.g. for at least Δ^9 THC and CBD). Following exposure to Fast

Blue B reagent, THC and THCA present as pink spots, while CBD and CBDA are orange in colour. Neutrals can be distinguished from the acids by comparison of the Rf value to that obtained for the standards. Identity is confirmed by comparison of Rf and colour of the sample spot, to that obtained for the appropriate standard.

A typical TLC protocol is as follows:

10

a) Materials and methods

Equipment:

Application device capable of delivering an accurately controlled volume of solution i.e 1 μ l capillary pipette or micro litre syringe.

15

TLC development tank with lid

20

Hot air blower

Silica gel G TLC plates (SIL N-HR/UV254), 200 μ m layer with fluorescent indicator on polyester support.

25

Dipping tank for visualisation reagent.

Mobile phase 80% petroleum ether 60:80/20% Diethyl ether.

30

Visualisation reagent 0.1% w/v aqueous Fast Blue B salt BN (Sigma Corp) (100mg in 100ml de-ionised water). An optional method is to scan at UV 254 and 365 nm.

35

b) Sample preparation

i) Herbal raw material

Approximately 200mg of finely ground, dried cannabis is weighed into a 10ml volumetric flask. Make up to volume using methanol:chloroform (9:1) extraction solvent.

Extract by ultrasound for 15 minutes. Decant supernatant and use directly for chromatography.

10 ii) Final products

The final products (crystalline CBD) are dissolved in methanol to a suitable concentration (which may be determined empirically) then used directly for chromatography. All sample preparations should produce a final concentration of about 0.5 mg/ml.

iii) Botanical drug substance

20 Accurately weigh approximately 50 mg of botanical drug substance into a 25 ml volumetric flask. Dissolve to make volume with HPLC grade methanol.

25 c) Standards

0.1 mg/ml Δ^9 -THC in methanol (Sigma).

0.1mg/ml CBD in methanol (Sigma).

30 The standard solutions are stored frozen at -20°C between uses and are used for up to 12 months after initial preparation.

d) Test solutions and method

35 Apply to points separated by a minimum of 10mm.

- i) either 5 μ l of herb extract or 1 μ l of pure cannabinoid/enriched extract solution or 1 μ l of diluted column eluate as appropriate,
- ii) 5 μ l of 0.1 mg/ml Δ^9 -THC in methanol standard solution,
- iii) 5 μ l of 0.1mg/ml CBD in methanol standard solution.

10 Dry the prepared plate with a hot air blower.

Place the base of the TLC plate in a development tank containing the mobile phase and saturated with vapour.

15 Elute the TLC plate through a distance of 8cm, then remove the plate. Allow solvent to evaporate from the plate and then repeat the elution for a second time (double development). Remove plate and allow it to dry in air.

20 The entire plate is briefly immersed in the Fast Blue B reagent until the characteristic red/orange colour of cannabinoids begins to develop. The plate is removed and allowed to dry under ambient conditions in the dark.

25

Cannabinoids will give an orange-purple colour:

Cannabidiol	CBD	orange (fastest running)
Δ^9 Tetrahydrocannabinol	THC	pink
Cannabinol	CBN	purple
Cannabichromene	CBC	pink purple
Cannabigerol	CBG	orange
Δ^9 tetrahydrocannabivarin	THCV	purple

30

35 The corresponding acids form streaks of the same colour as the neutral component spots. The acids run at lower R_f .

Claims

1. A method of obtaining substantially pure cannabidiol (CBD) from plant material, which method
5 comprises obtaining a cannabidiol-containing extract of the plant material, dissolving the extract in a solvent to form a solution, removing insoluble material from this solution and evaporating the solvent from the solution to obtain substantially pure
10 cannabidiol.

2. A method according to claim 1 wherein the insoluble material is removed by filtration.

15 3. A method according to claim 1 or claim 2 wherein the solvent is a non-polar solvent.

4. A method according claim 3 wherein the non-polar solvent is substantially less polar than
20 cannabidiol such that impurities which are more polar than cannabidiol are removed.

5. A method according to claim 4 wherein the non-polar solvent is a C5-C12 straight chain or
25 branched alkane or a carbonate ester of a C1-C12 alcohol.

6. A method according to claim 5 wherein the non-polar solvent is pentane, hexane or propyl
30 carbonate.

7. A method according to claim 6 wherein the non-polar solvent is pentane.

35 8. A method as claimed in any of the preceding claims wherein the cannabidiol-containing extract of the plant material is a botanical drug substance (BDS) derived from the plant material.

9. A method according to claim 8 wherein the botanical drug substance is prepared by a process comprising solvent extraction of the plant material.

5

10. A method according to claim 9 wherein the botanical drug substance is prepared by extraction with carbon dioxide, ethanol, methanol or hexane.

10

11. A method according to claim 10 wherein the botanical drug substance is prepared by a process comprising extraction with carbon dioxide (CO₂), followed by a secondary extraction step to remove a proportion of the non-target materials.

15

12. A method according to claim 11 wherein the secondary extraction step is ethanolic precipitation.

20

13. A method according to claim 11 or claim 12 which further includes a charcoal clean-up step.

25

14. A method according to claim 13 wherein the botanical drug substance is prepared by a process comprising:

30

- i) decarboxylation of the plant material,
- ii) extraction with liquid CO₂, to produce a crude botanical drug substance,
- iii) precipitation with C1-C5 alcohol to reduce the proportion of non-target materials,
- iv) removal of the precipitate,
- v) treatment of the resulting solution with activated charcoal, and
- vi) removal of C1-C5 alcohol and water, thereby producing a final botanical drug substance.

35

15. A method of obtaining substantially pure cannabidiol (CBD) from plant material comprising:
i) decarboxylation of the plant material,

- ii) extraction with liquid CO₂, to produce a crude botanical drug substance,
- iii) precipitation with ethanol to reduce the proportion of non-target materials,
- 5 iv) filtration to remove the precipitate,
- v) treatment of the resulting solution with activated charcoal,
- vi) removal of ethanol and water from the solution to produce a CBD-enriched extract,
- 10 v) re-dissolving the CBD-enriched extract in a non-polar solvent that is substantially less polar than cannabidiol such that impurities which are more polar than cannabidiol are removed,
- vi) removal of solvent from the solution of step v) to
- 15 obtain substantially pure CBD.

16. A method according to claim 15 wherein the non-polar solvent of step v) is pentane.

- 20 17. A method according to any one of claims 1 to 16 wherein the substantially pure cannabidiol is obtained in crystalline form.

- 25 18. A substantially pure preparation of cannabidiol (CBD) having a chromatographic purity of 95% or greater, preferably 96% or greater, more preferably 97% or greater, more preferably 98% or greater, preferably 99% or greater, and most preferably 99.5% or greater by area normalisation of
- 30 an HPLC profile.

- 19. A substantially pure preparation of cannabidiol according to claim 18 which is a white crystalline solid at room temperature.

35

- 20. A substantially pure preparation of cannabidiol according to claim 19 which has a melting point in the range of from 64 to 66°C.

21. A substantially pure preparation of cannabidiol according to any one of claims 18 to 20 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% and most preferably less than 0.1% Δ^9 THC.

22. A substantially pure preparation of cannabidiol according to any one of claims 18 to 21 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% and most preferably less than 0.1% CBN.

23. A substantially pure preparation of cannabidiol according to any one of claims 18 to 22 which is obtainable from cannabis plant material using a method comprising:


- i) decarboxylation of the plant material,
- ii) extraction with liquid CO_2 , to produce a crude botanical drug substance,
- iii) precipitation with ethanol to reduce the proportion of non-target materials,
- iv) filtration to remove the precipitate,
- v) treatment of the resulting solution with activated charcoal,
- vi) removal of ethanol and water from the solution to produce a CBD-enriched extract,
- v) re-dissolving the CBD-enriched extract in pentane,
- vi) removal of pentane from the solution of step v) to obtain substantially pure CBD.

24. A substantially pure preparation of cannabidiol substantially as described herein and having an HPLC profile substantially as shown in Figure 3.

Fig. 1

1/4

TLC profiles of BDS starting material and purified CBD



CHROMATOGRAPHIC CONDITIONS:

Stationary phase: SIL G/UV₂₅₄

Mobile phase: Hexane: diethyl ether 80:20

Development distance: double development.

Visualisation: 0.1% w/v Fast Blue B salt in water

Standards 1 mg/ml CBD (BN 10601/C) in MeOH
5 ul applied to TLC plate.
1 mg/ml d9 THC (BN 10601/B) in MeOH
5 ul applied to TLC plate.

Samples 1 mg/ml CBD STARTING MATERIAL in MeOH
5 ul applied to TLC plate.
1 mg/ml CRYSTALLINE CBD in MeOH
5 ul applied to TLC plate.

HPLC profiles of BDS starting material and purified CBD






Fig. 3.

Comparison of HPLC profiles of commercially available CBD standard (ex Sigma) and In house purified CBD




GC profiles of BDS starting material and purified CBD



PCT Application

GB0304086



This Page Blank (uspto)